Physician profile
Tram Tran
NPI 1619170826
$6,176.37
in general payments reported to CMS, 2019-2025
32 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $963 · 2022: $754 · 2023: $1,224 · 2024: $1,805 · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,459.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,634.88 | 2021-2025 | |
| Valinor Pharma, LLC | $501.46 | 2023-2025 | Movantik |
| Scilex Pharmaceuticals INC. | $413.82 | 2022-2025 | Ztlido, Elyxyb |
| Azurity Pharmaceuticals, INC. | $373.88 | 2023-2025 | Horizant, Horizant |
| Collegium Pharmaceutical, INC. | $327.29 | 2022-2025 | Belbuca, Xtampza |
| Abbott Laboratories | $290.96 | 2023 | Proclaim |
| Bioventus LLC | $248.79 | 2021-2025 | Supartz Fx Sodium Hyaluronate, Gelsyn-3, Supartz Fx Sodium Hyaluronate |
| Biohaven Pharmaceutical Holding Company LTD. | $246.02 | 2022 | |
| Redhill Biopharma INC. | $217.91 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $200.86 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.57 | 2021-2025 | Relistor |
| Virtus Pharmaceuticals LLC | $181.60 | 2021-2024 | Levorphanol Tartrate |
| Protega Pharmaceutials INC | $165.71 | 2025 | Roxybond |
| Orexo US, INC. | $163.82 | 2021-2025 | Zubsolv |
| Axsome Therapeutics, INC. | $136.21 | 2025 | Symbravo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $135.12 | 2021-2022 | |
| Indivior INC. | $133.83 | 2022-2025 | Sublocade |
| Cumberland Pharmaceuticals, INC. | $83.32 | 2024-2025 | Kristalose |
| Pfizer INC. | $78.00 | 2023-2024 | |
| Medtronic, INC. | $75.65 | 2021-2024 | Intellis Adaptivestim, Synchromedii |
| Braeburn INC. | $74.76 | 2023-2025 | Brixadi |
| Forte Bio-Pharma LLC | $73.22 | 2021 | |
| Allergan, INC. | $70.19 | 2021-2022 | |
| Saluda Medical Americas, INC. | $26.89 | 2025 | Evoke |
| Arbor Pharmaceuticals, INC. | $20.00 | 2022 | |
| Lilly USA, LLC | $18.86 | 2022 | |
| Boston Scientific Corporation | $18.72 | 2021 | |
| Grt US Holding, INC. | $18.59 | 2021 | |
| Ibsa Pharma INC. | $17.99 | 2021 | |
| Tersera Therapeutics LLC | $15.88 | 2023 | Prialt |
| Pacira Pharmaceuticals Incorporated | $15.34 | 2024 | Iovera, Exparel |
| Idorsia Pharmaceuticals US INC | $14.23 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tram Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.